KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

KalVista Pharmaceuticals (NASDAQ:KALV) had its price target lifted by stock analysts at Needham & Company LLC from $35.00 to $36.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price target indicates a potential upside of 89.97% from the company’s previous close.

A number of other equities analysts have also commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Thursday, January 22nd. HC Wainwright raised their target price on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research note on Friday, January 9th. TD Cowen reaffirmed a “buy” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. Finally, Wall Street Zen upgraded KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, KalVista Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.60.

KalVista Pharmaceuticals Stock Up 10.6%

Shares of NASDAQ:KALV opened at $18.95 on Wednesday. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18. KalVista Pharmaceuticals has a 52-week low of $9.23 and a 52-week high of $19.27. The company has a 50 day moving average of $15.95 and a two-hundred day moving average of $14.44. The company has a market capitalization of $957.92 million, a price-to-earnings ratio of -4.80 and a beta of -0.35.

Insider Activity at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, CFO Brian Piekos sold 1,767 shares of the stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $15.57, for a total transaction of $27,512.19. Following the transaction, the chief financial officer directly owned 13,762 shares in the company, valued at $214,274.34. This represents a 11.38% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Nicole Sweeny sold 3,975 shares of the firm’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total transaction of $61,890.75. Following the transaction, the insider directly owned 47,003 shares of the company’s stock, valued at approximately $731,836.71. This represents a 7.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 33,378 shares of company stock valued at $522,290. Insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several large investors have recently modified their holdings of KALV. Vanguard Group Inc. grew its stake in KalVista Pharmaceuticals by 3.7% in the third quarter. Vanguard Group Inc. now owns 2,501,119 shares of the specialty pharmaceutical company’s stock worth $30,464,000 after purchasing an additional 88,720 shares in the last quarter. Tudor Investment Corp ET AL acquired a new stake in KalVista Pharmaceuticals during the third quarter valued at approximately $24,360,000. State Street Corp lifted its holdings in KalVista Pharmaceuticals by 21.3% during the 4th quarter. State Street Corp now owns 1,911,691 shares of the specialty pharmaceutical company’s stock worth $30,874,000 after buying an additional 336,195 shares during the last quarter. Vestal Point Capital LP grew its position in shares of KalVista Pharmaceuticals by 152.0% in the 4th quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock worth $30,524,000 after acquiring an additional 1,140,000 shares in the last quarter. Finally, Parkman Healthcare Partners LLC grew its position in shares of KalVista Pharmaceuticals by 155.5% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock worth $21,132,000 after acquiring an additional 1,055,940 shares in the last quarter.

Key Stories Impacting KalVista Pharmaceuticals

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Company reported $49.1M in EKTERLY revenue during an eight‑month transition period and highlighted a strong launch that supports topline growth expectations. KalVista posts $49.1 million in EKTERLY revenue
• Positive Sentiment: Corporate update and eight‑month FY2025 results emphasized commercial progress and operational updates that underpin near‑term revenue visibility. KalVista Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update
• Positive Sentiment: Stifel Nicolaus raised its price target to $42 and kept a “buy” rating — implying ~122% upside from the current price — reflecting bullish analyst views on commercial execution and upside potential. Stifel raises KALV price target
• Positive Sentiment: Needham & Company increased its target from $35 to $36 and maintained a “buy” rating, signaling continued analyst confidence in EKTERLY’s market opportunity. Needham raises KALV price target
• Neutral Sentiment: Q1/8‑month earnings call transcripts (and related highlights) are available; these provide detail on revenue cadence, channel dynamics, and management commentary that investors should review for execution risk and guidance clarity. Q1 2025 earnings call transcript 8 Months 2025 earnings call transcript
• Negative Sentiment: Citizens Jmp trimmed its price target from $29 to $28 and moved to “market outperform” — a mild downgrade in target that could temper enthusiasm despite still-significant upside (~48%). Citizens Jmp lowers KALV price target

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.